BRTX (STOCKS)
BioRestorative Therapies, Inc. Common Stock (NV)
$0.259600
+0.019000 (+7.90%)
Prev close: $0.240600
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Lance Alstodt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6.56M
- Employees
- 11
- P/E (TTM)
- -0.15
- P/B (TTM)
- 6.23
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.31 | $-0.38 | +0.0674 | +17.86% |
|
Sep 2025 (Q3)
|
$-0.33 | $-0.37 | +0.0372 | +10.13% |
|
Jun 2025 (Q2)
|
$-0.30 | $-0.39 | +0.0876 | +22.60% |
|
Mar 2025 (Q1)
|
$-0.64 | $-0.33 | -0.3085 | -93.06% |
Financial Statements
| Revenues | $359.70K |
| Benefits Costs and Expenses | $14.56M |
| Cost Of Revenue | $23.84K |
| Costs And Expenses | $14.56M |
| Gross Profit | $335.86K |
| Nonoperating Income/Loss | $1.41M |
| Operating Expenses | $15.98M |
| Depreciation and Amortization | $209.99K |
| Research and Development | $10.09M |
| Other Operating Expenses | $5.68M |
| Operating Income/Loss | -$15.65M |
| Income/Loss From Continuing Operations After Tax | -$14.20M |
| Income/Loss From Continuing Operations Before Tax | -$14.20M |
| Interest And Dividend Income, Operating | $270.57K |
| Interest Income/Expense After Provision For Losses | $266.21K |
| Interest Income/Expense Operating, Net | $266.21K |
| Net Income/Loss | -$14.24M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$14.24M |
| Net Income/Loss Available To Common Stockholders, Basic | -$14.24M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$1.58 |
| Diluted Earnings Per Share | -$1.58 |
| Basic Average Shares | 8,993,115 |
| Diluted Average Shares | 8,993,115 |
| Assets | $4.08M |
| Current Assets | $3.14M |
| Noncurrent Assets | $942.77K |
| Fixed Assets | $358.77K |
| Intangible Assets | $534.20K |
| Other Non-current Assets | $49.81K |
| Liabilities | $3.72M |
| Current Liabilities | $3.72M |
| Accounts Payable | $1.34M |
| Wages | $713.50K |
| Other Current Liabilities | $1.67M |
| Noncurrent Liabilities | $0.00 |
| Equity | $356.74K |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $356.74K |
| Liabilities And Equity | $4.08M |
| Net Cash Flow From Operating Activities | -$10.79M |
| Net Cash Flow From Operating Activities, Continuing | -$10.79M |
| Net Cash Flow From Investing Activities | $8.90M |
| Net Cash Flow From Investing Activities, Continuing | $8.90M |
| Net Cash Flow From Financing Activities | $2.85M |
| Net Cash Flow From Financing Activities, Continuing | $2.85M |
| Net Cash Flow | $963.30K |
| Net Cash Flow, Continuing | $963.30K |
| Comprehensive Income/Loss | -$14.24M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$14.24M |
| Other Comprehensive Income/Loss | $0.00 |